Epilepsy Drugs in the Pipeline
Presented by Claude Steriade, MD, MSCI

In 2020, there are about two dozen therapies now FDA approved to treat different forms of epilepsy, with many more in the pipeline. The discovery of new receptors and pathways that can lead to seizures has enabled the development of new compounds. In addition, our understanding of the causes of epilepsy has opened up new treatment approaches in specific types of genetic and inflammatory epilepsies. In this lecture, recently approved antiseizure medications will be discussed, and a glimpse into what's to come in the coming years will be explored.

About the presenter: Dr. Claude Steriade is an assistant professor of neurology and joined the NYU Langone Comprehensive Epilepsy Center two years ago after training at the Cleveland Clinic. As an adult epileptologist, her main areas of clinical and research interests lie in the investigation of novel causes of epilepsy, specifically autoimmune and neuro-inflammatory diseases, and their translation into novel treatments. She is also the NYU lead on multiple clinical trials of novel antiseizure medications for focal and generalized epilepsy.

Thursday, September 10, 2020
3:30 – 5:00pm EST
Online via WebEx. Click here to register.

This lecture is sponsored by:

Greenwich BioSciences
Ovid Therapeutics

Please register by Wednesday, September 9, 2020 via WebEx link
For questions, please contact facesinfo@nyulangone.org